Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. Show more
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0164 | 2.85415941525 | 0.5746 | 0.65 | 0.563 | 16504 | 0.62406507 | CS |
4 | -0.2372 | -28.6404250181 | 0.8282 | 1.1099 | 0.54 | 704263 | 0.87733091 | CS |
12 | -0.183 | -23.6434108527 | 0.774 | 1.1099 | 0.5 | 244277 | 0.87304224 | CS |
26 | -1.059 | -64.1818181818 | 1.65 | 1.87 | 0.5 | 122626 | 0.90439319 | CS |
52 | -0.539 | -47.6991150442 | 1.13 | 1.87 | 0.5 | 66876 | 0.91543165 | CS |
156 | -6.769 | -91.9701086957 | 7.36 | 9.4 | 0.5 | 64065 | 3.90672291 | CS |
260 | -14.369 | -96.0494652406 | 14.96 | 19.56 | 0.5 | 348933 | 10.81943899 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.